T1	Participants 51 89	bone turnover in postmenopausal women.
T2	Participants 120 171	accelerated bone loss following estrogen cessation.
T3	Participants 371 404	postmenopausal, osteopenic women.
T4	Participants 405 430	Women aged 50 to 80 years
T5	Participants 501 578	raloxifene (group 1, n=20) or placebo (group 2, n=20) for a further 96 weeks.
T6	Participants 579 631	A third group (group 3, n=14) received no treatment.
T7	Participants 1381 1403	accelerated bone loss.
